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Introduction: We previously demonstrated that a family predisposed 
to lung cancer harbored a V843I substitution in the epidermal growth 
factor receptor (EGFR) protein. We report here the further character-
ization of this mutant EGFR protein in the context of tumorigenicity 
and resistance to tyrosine kinase inhibitors (TKIs) of EGFR activity.
Methods: Phosphorylation of EGFR and downstream signaling pro-
teins of lung adenocarcinoma cell lines with EGFR mutations was 
assayed by flow cytometry. Susceptibility to TKIs of these cell lines, 
with or without suppression of mutant EGFR expression by small 
inhibitory RNA (siRNA), was investigated using a cellular viability 
assay. Furthermore, protein modeling was used to predict TKI bind-
ing to EGFR protein carrying the V843I mutation.
Results: Phosphorylation of EGFR and downstream signaling pro-
teins was elevated upon transfection with an EGFR gene with the 
V843I. Although the cell line with V843I + L858R demonstrated 
resistance to EGFR-TKIs, the cells became susceptible to TKIs upon 
incubation with siRNA specific for the V843I allele. The structural 
analysis suggested that TKI binding to EGFR would be sterically 
hindered by Arg841 in the double-mutant (V843I + L858R) EGFR.
Conclusions: The V843I mutation contributes to tumorigenesis by pro-
moting phosphorylation of EGFR and its downstream signaling pro-
teins. This mutation also appears to provide resistance to EGFR-TKIs 
through structural modification of EGFR. These features are compa-
rable with those in EGFR T790M mutation, suggesting that cases with 
germ-line V843I or T790M mutations could be categorized as a class of 
familial lung cancer syndrome with resistance to EGFR-TKIs.
Key Words: Susceptibility, Small inhibitory RNA, Crystallographic 
analysis, T790M, L858R, Lung adenocarcinoma
(J Thorac Oncol. 2014;9: 1377–1384)
Recent works have identified a series of somatic mutations that render lung tumors susceptible to tyrosine kinase 
inhibitors (TKIs) of the epidermal growth factor receptor 
(EGFR).1–3 These mutations were located in exons 18 to 21 
of the gene encoding EGFR. However, a secondary resis-
tance mutation, T790M located in exon 20 of EGFR, has 
been detected in more than half of patients showing disease 
progression after TKI therapy.4,5 Interestingly, this T790M 
mutation was also identified in familial lung adenocarcinoma 
cases, suggesting that this mutation may also be associated 
with familial predisposition to lung cancer.6,7
We recently have reported a family predisposed to lung 
adenocarcinoma that presented with another EGFR germ-
line mutation, V843I.8 All tested lung adenocarcinomas in 
this family harbored the V843I-encoding mutation, together 
with a secondary mutation L858R. These results suggested 
that V843I mutation may serve as the “first hit” rendering 
cells susceptible to tumorigenic secondary mutations in 
EGFR. Interestingly, a tumor cell line derived from lung 
adenocarcinoma cells harboring the double-mutant EGFR 
(encoding V843I + L858R) was resistant to EGFR-TKI 
(AG1478); a proband case with lung adenocarcinoma was, 
in fact, clinically resistant to gefitinib therapy at initial treat-
ment.8 Together, these results are comparable with those seen 
in EGFR with the T790M mutation. In both instances, a mis-
sense mutation in EGFR was associated with predisposition 
to lung cancer in pulmonary cells and resistance to EGFR-
TKIs in tumor cells. Most recently, an inherited mutation of 
the HER2 gene has been found to be responsible for familial 
lung cancer susceptibility in nonsmokers. Therefore, inves-
tigations are needed to explore the molecular mechanisms 
underlying the association of these mutations with lung can-
cer susceptibility.9
Although somatic or germ-line V843I mutation has 
been reported in lung cancer patients by several groups,10–15 
no functional study has, to our knowledge, demonstrated 
the association of a V843I mutation with tumorigenicity 
or resistance to EGFR-TKI. To address these issues, we 
investigated the properties of cell lines harboring the EGFR 
V843I, including the use of allele-specific targeting with 
small inhibitory RNA (siRNA) to overcome resistance to 
EGFR-TKIs.
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MATERIALS AND METHODS
Cell Lines
Lung adenocarcinoma cell line KCI-PLA1 was derived 
from tumor cells obtained from pleural effusion of the pro-
band, a member of the family with a germ-line V843I EGFR 
mutation. DNA sequencing confirmed the presence of the 
EGFR with mutations (V843I + L858R) in this cell line.8 Lung 
adenocarcinoma cell lines NCI-H1975 harboring mutation of 
L858R and T790M, 11–18 harboring mutation of L858R, and 
A549 harboring wild-type (wt) EGFR were purchased from 
The American Type Culture Collection (Manassas, VA).16 All 
of these cell lines were maintained in RPMI supplemented 
with 10% fetal bovine serum, 10 units/ml penicillin, and 10 
units/ml streptomycin (Life Technologies, Grand Island, NY). 
The NIH-3T3 cell line (harboring wt EGFR) was maintained 
in DMEM supplemented with 10% fetal bovine serum, 10 
units/ml penicillin, and 10 units/ml streptomycin. All cell 
lines were grown at 37°C in a humidified 5% CO
2
 atmosphere.
Plasmids, EGFR Mutant Constructs, 
and Transfection
A pCMV6-Entry plasmid carrying human wt EGFR 
transcript variant 1 was purchased from OriGene Technologies 
(Rockville, MD). This plasmid encodes EGFR with C-terminal 
Myc and DDK (FLAG) tags. Mutations encoding V843I and/
or L858R were introduced into the EGFR plasmid using the 
QuickChange Site-Directed Mutagenesis kit (Stratagene, La 
Jolla, CA). NIH-3T3 cells were transfected by electroporation 
with 10 μg of each of the following plasmids: pCMV6-Entry 
empty vector, pCMV6-Entry-wt EGFR, pCMV6-Entry-
EGFR V843I, pCMV6-Entry-EGFR L858R, and pCMV6-
Entry-EGFR V843I + L858R. These cells were designated 
as vector-3T3, wtEGFR-3T3, V843I-3T3, L858R-3T3, and 
V843I/L858R-3T3, respectively. After selection at 0.6 mg/ml 
G418 (Life Technologies) for 28 days, transfection was con-
firmed by flow cytometry using an anti-Myc antibody (Cell 
Signaling Technology, Beverly, MA). Myc-positive cells were 
then maintained in the same medium for further study.
Transforming Ability
Transforming ability of EGFR mutations mentioned 
above was investigated by colony formation assays in liquid 
medium by a standard method.
Antibodies and Flow Cytometry
Phosphorylation of signaling pathway proteins down-
stream of EGFR was determined by flow cytometry as described 
previously.17 Briefly, NIH-3T3 cells stably transfected by wt or 
mutant EGFR were incubated overnight (16 hours) in Dulbecco’s 
Modified Eagles Medium without fetal bovine serum. Cells were 
trypsinized (0.05 % trypsin-ethylenediaminetetraacetic acid) for 
5 minutes, epithelial growth factor (EGF) was added to 30 ng/ml, 
and cells were incubated for another 5 minutes. After washing, 
cells were fixed by 750 μL of BD Cytofix/Cytoperm Fixation/
Permeabilization solution (Beckton Dickinson, Franklin Lakes, 
NJ) for 20 minutes. After washing, 1 × 106 cells were stained with 
fluorescence (Alexa Fluor 488, Life Technologies)-conjugated 
antibodies with specificity for phosphorylated human EGFR 
(pY1068; R&D Systems, Minneapolis, MN), phosphorylated 
murine ERK1/2 (pT202/pY204; BD), phosphorylated murine 
Akt (pS473) (Cell Signaling Technology), or phosphorylated 
murine STAT5 (pY694; BD). After washing, cells were sus-
pended in permeabilization/wash buffer (BD) and subjected to 
flow cytometry for scoring the percentage of cells expressing the 
respective phosphorylated protein.
Growth Inhibition Assay
Growth inhibition by erlotinib, gefitinib, afatinib, dacomi-
tinib, or AG1478 (Cell Signaling Technology), an EGFR-TKI 
analogous to gefitinib, was assessed by the MTS assay using 
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI) as previously described.18
siRNA Targeting EGFR
To test whether the V843I-encoding mutation actually 
contributes to the resistance to AG1478, we investigated the 
susceptibility to AG1478 in V843I (+) and V843I (−) cell 
lines by inhibiting EGFR with two pairs of mutation-specific 
siRNAs. Oligonucleotides for siRNA targeting the V843I-
encoding EGFR were designed using the siDirect website 
(http://design.RNAi.jp). The sequences of the paired oligo-
nucleotides comprising the siRNAs were as follows; siRNA1, 
5′-GAA CAU ACU GGU GAA AAC ATT-3′ (sense) and 
5′-UGU UUU CAC CAG UAU GUU CTT-3′ (antisense); 
siRNA2, 5′-GAA CAU ACU GGU GAA AAC ACC-3′ (sense) 
and 5′-UGU UUU CAC CAG UAU GUU CCU-3′ (antisense). 
These siRNAs were purchased from Japan Bio Services Co., 
Ltd. (Saitama, Japan). V843I-specific siRNAs or negative 
control siRNA (Stealth RNAi Negative Control Duplexes, 
Life Technologies) was added to the cell lines (KCI-PLA1, 
NCI-H1975, 11–18, and A549) to 100 nM, and sensitivity 
to AG1478 was determined by the MTS assay as described 
above. For detection of apoptosis in cells treated by siRNA1, 
Annexin-V FITC Kit System (Beckman Coulter, Marseille, 
France) was used according to the manufacturer’s instruction.
Protein Structural Analysis
To predict TKI binding to EGFR protein harboring the 
V843I substitution, homology protein models were built using 
the program DS modeling version 2.0 (Accelrys, San Diego, 
CA) based on the crystallographic structure of the EGFR pro-
tein kinase domain, solved in complex with erlotinib (PDB 
code: 1M17). Based on this structure, the entire kinase domain 
of the receptor protein (residues 672–964) and each inhibitor 
were selected for simulations.19 The energy minimization of 
each mutant homology protein structure was carried out using 
the CHARMm energy function.20
Statistical Analysis
The significance of differences was tested using two-
tailed Student’s t test for paired data. All statistical calcula-
tions were performed using SPSS version 11.0 software for 
Windows (SPSS, Chicago, IL). All statistical tests were two-
tailed and differences were judged statistically significant at 
values of p less than 0.05.
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RESULTS
Transforming Ability
By the colony formation assay, colony-forming rates of 
NIH-3T3 cells transfected by genes encoding wild-type EGFR, 
EGFR L858R, EGFR V843I, and EGFR V843I + L858R were 
0.228 ± 0.107, 0.828 ± 0.286, 0.686 ± 0.333, and 0.569 ± 0.058, 
respectively. Therefore, the last three EGFR mutations showed 
significantly higher colony-forming ability than wild-type 
EGFR (p = 0.03, 0.02, and 0.008 for L858R versus wt, V843I 
versus wt, and V843I/L858R versus wt, respectively).
Effects of Mutant EGFR on Cell Signaling
To determine the effect of the V843I-encoding muta-
tion on cell signaling, cells were assessed for phosphorylation 
of EGFR at Y1068 (pEGFR; Fig. 1A). Similar assays were 
performed for phosphorylation of STAT5 at Y694 (pSTAT5; 
Fig. 1B), of ERK1/2 at T202/Y204 (pERK1/2; Fig. 1C), and 
of Akt at S473 (pAkt; Fig. 1D).
Although the percentage of cells with pEGFR was 
higher in V843I-3T3 than in wtEGFR-3T3, the difference was 
not statistically significant. Upon EGFR stimulation, the per-
centage of V843I-3T3 cells with pEGFR was elevated com-
pared with the pEGFR level before stimulation. Consequently, 
the percentage of cells with pEGFR was significantly higher in 
V843I-3T3 compared with that in wtEGFR-3T3 (p = 0.001). 
Similar elevations in pEGFR after EGF stimulation were not 
seen in the parent cell line (NIH-3T3) or other transfected cell 
lines (vector-3T3, wtEGFR-3T3, L858R-3T3, and V843I/
L858R-3T3). However, L858R-3T3 showed a significantly 
higher level of pEGFR than wtEGFR-3T3 (p < 0.001).
The percentage of cells with pSTAT5 or pERK1/2 
before EGFR stimulation showed no difference between 
V843I-3T3 or L858R-3T3 and wtEGFR-3T3. After EGF 
stimulation, the percentages of cells with pSTAT5 and 
EGFR STAT5
ERK 1/2 Akt
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FIGURE 1.  Phosphorylation assay of EGFR and its downstream signal proteins by flow cytometry. The black and white columns 
indicate the mean percentages of cells with (A) EGFR phosphorylated at Y1068 (pEGFR), (B) STAT5 phosphorylated at Y694 
(pSTAT5), (C) ERK1/2 phosphorylated at T202/Y204 (pERK1/2), and (D) Akt phosphorylated at Ser473 (pAkt), before and after 
epithelial growth factor (EGF) stimulation, respectively. Each experiment was performed three times. *p less than 0.05, com-
pared with wtEGFR-3T3 under stimulation of EGF. Bars indicate standard deviations.
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pERK1/2 were elevated compared with those before stimula-
tion in V843I-3T3 and L858R-3T3. Notably, the percentages 
of cells with pSTAT5 and pERK1/2 were significantly higher 
in V843I-3T3 compared with that in wtEGFR-3T3 (pSTAT5: 
p = 0.001, pERK1/2: p = 0.008). After stimulation by EGF, 
the percentage of cells with pSTAT5 and pERK1/2 did not 
increase significantly in NIH-3T3, vector-3T3, and V843I/
L858R-3T3 cells.
In contrast to the other signaling proteins, levels of pAkt 
were not significantly altered by stimulation with EGF in any 
of the tested cells. Furthermore, pAkt levels did not differ sig-
nificantly among all tested cells, either before or after EGF 
stimulation.
Effect of EGFR on TKI Susceptibility
Cell lines with distinct EGFR genotype were tested for 
EGFR-TKI susceptibility using a cell viability (MTS) assay 
(Fig. 2). Cell lines KCI-PLA1 (harboring EGFR L858R + 
V843I), NCI-H1975 (harboring EGFR L858R + T790M), and 
A549 (harboring wt EGFR) were resistant to erlotinib (Fig. 
2A) and gefitinib (Fig. 2B), with 50% inhibitory concentra-
tion greater than 10 μM for each of these TKIs. In contrast, 
cell line 11–18 (expressing EGFR L858R) was susceptible 
to both EGFR-TKIs, with 50% inhibitory concentration of 
~0.5 μM. Similar susceptibility/resistance profiles were seen 
for AG1478 (another TKI; Fig. 3), consistent with a previous 
report testing AG1478 susceptibility using the MTS assay.8 
Notably, KCI-PLA1 also showed resistance against afatinib 
and dacomitinib, second-generation EGFR-TKIs that are 
effective for lung cancer that encodes the T790M mutant 
EGFR (Fig. 2C).21
Effect of siRNA on Susceptibility to EGFR-TKI
To test the contribution of the EGFR substitutions 
to TKI susceptibility, we repeated the cell viability assays 
in combination with allele-specific targeting by siRNAs 
(Fig. 3). These small inhibitory RNAs were expected to 
interfere selectively with the transcription, translation, and/
or stability of the corresponding allele/transcript of EGFR. 
In the absence of V843I-specific siRNA, 10 μM AG1478 did 
not inhibit growth of KCI-PLA1 cells, and a substantial frac-
tion of KCI-PLA1 cells was viable even at 100 μM AG1478 
(Fig. 3A). However, in the presence of 100 nM of V843I-
specific siRNA1, 40% of the KCI-PLA1 cells were killed at 
10 μM AG1478, and almost all cells were dead at 100 μM 
AG1478 (Fig. 3A). The cell viability at 10 μM of AG1478 
was significantly lower in the presence of V843I-specific 
siRNA1 than in the presence of control siRNA (p = 0.03), 
demonstrating that the sensitization by siRNA1 was sequence 
dependent (Fig. 3A). In contrast, addition of V843I-specific 
siRNA1 showed no significant effect on the cell toxicity at 
10 or 100 μM AG1478 compared with the addition of control 
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FIGURE 2.  MTS assay for susceptibility of lung adenocarcinoma cell lines to (A) erlotinib (B) gefitinib, and (C) afatinib and 
dacomitinib. KCI-PLA1 was resistant to gefitinib, erlotinib, afatinib, or dacomitinib at concentrations of up to 10-100 μM. Each 
experiment was repeated three times. Bars indicate standard deviations.
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siRNA in NCI-1975, confirming the allele-specific nature 
of this effect (Fig. 3B). Addition of V843I-specific siRNA1 
showed no effect on the cell toxicity by AG1478 compared 
with addition of control siRNA in 11–18 and A549 (Fig. 3C, 
KCI-PLA1
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FIGURE 3.  Effect of EGFR V843I-specific siRNA on susceptibility of lung adenocarcinoma cell lines to EGFR-tyrosine kinase 
inhibitors AG1478. A, Cell viability of KCI-PLA1 (with V843I and L858R) in the presence of 10 or 100 μM of AG1478 was elimi-
nated by addition of 100 nM of V843I-specific siRNA1, whereas this effect was not evident upon addition of nonspecific siRNA. 
(B–D) Addition of V843I-specific siRNA1 did not affect cell viability of NCI-1975, 11–18, or A549 compared with addition of 
nonspecific siRNA. Each experiment was repeated three times. Bars indicate standard deviations. (E, F) Apoptosis of KCI-PLA1 
cells treated by siRNA alone (E) or siRNA + AG1478 (F). FL1 denotes the fluorescence intensity of annexin-positive cells, and FL2 
denotes the fluorescence intensity of propidium iodide-positive cells. A large part of dead cells displayed an apoptotic pattern 
(right lower quadrant). Note that few cells were dead (annexin-positive) when treated by siRNA alone.
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D). Experiments using siRNA2 (another siRNA specific to 
V843I) produced similar results (Supplementary Figure 1, 
SDC1, http://links.lww.com/JTO/A612). In the analysis of 
apoptosis by flow cytometry, a large part of the cells killed 
by siRNA in the presence or absence of AG1478 displayed an 
apoptotic pattern (Fig. 3, E and F).
TKI Binding Site Structure of 
EGFR V843I Mutant
To predict TKI binding to EGFR protein, protein homol-
ogy modeling of the TKI binding site structures was carried 
out based on the structure of the EGFR kinase domain in com-
plex with erlotinib. EGFR proteins with wild-type sequences 
or with the L858R or T790M substitution are predicted to 
display similar structures for the TKI binding site (Fig. 4A-
C, respectively). However, double-mutated EGFR (L858R + 
V843I) is predicted to have an altered TKI binding site, with 
the R841 side chain sterically hindering entrance to the site 
(Fig. 4D). In contrast, such a block by the R841 side chain is 
not predicted in the model of double-mutated EGFR (L858R 
+ T790M). Instead, the TKI binding site pocket is predicted 
to be expanded because of the different arrangements of the 
F856 and R858 side chains in comparison with those of the 
L858R-substituted EGFR (Fig. 4E).
DISCUSSION
In previous studies, V843I and T790M mutations were 
reported to share features of lung cancer susceptibility and 
resistance to TKIs.8,11,15 However, the mechanisms underly-
ing these properties remain largely unknown. In particular, 
the role of the V843I substitution in EGFR is poorly char-
acterized, probably because of the low frequency of the cor-
responding mutation in lung cancer. Indeed, other than three 
families with germ-line V843I mutations, to our knowledge, 
only four sporadic cases have been reported in the literature. 
In the most recent report of lung cancer data in the COSMIC 
database, V843I accounted for only 0.05% of all registered 
EGFR mutations, compared with the higher frequency of 
T790M, which accounted for approximately 3% of all muta-
tions.22 The present study, for the first time, corroborates the 
hypothesized dual role of the V843I mutation in tumorigen-
esis and TKI drug resistance.
In the colony formation assay, NIH-3T3 cells harbor-
ing EGFR V843I or EGFR V843I + L858R showed higher 
levels of transformation compared with NIH-3T3 cells har-
boring wild-type EGFR, confirming the oncogenicity of the 
EGFR V843I mutation in both the presence and absence of the 
accompanying L858R mutation. In phosphorylation assays, 
EGFR, together with its downstream signaling proteins 
STAT5 and ERK1/2, displayed increased phosphorylation in 
NIH-3T3 cells expressing EGFR V843I. The phosphoryla-
tion of these proteins was enhanced by the addition of EGF. 
These features were similar to those seen in cells expressing 
EGFR with L858R or T790M single mutation, indicating that 
the V843I mutation of EGFR confers tumorigenic proper-
ties to lung cells.23–26 In contrast, no elevation in phosphor-
ylation of EGFR, ERK1/2, or STAT5 was observed in cells 
expressing the V843I + L858R double-mutant EGFR. These 
results were confirmed by immunochemiluminescence assays 
(Human Phospho-Receptor Tyrosine Kinase Array Kit, R&D 
Systems), suggesting a difference in kinase activity between 
EGFR V843I + L858R and EGFR T790M + L858R (data not 
shown). Such a discrepancy may contribute to the difference 
in prevalence between secondary T790M and V843I mutations 
in relapsed lung cancer that harbors primary TKI-sensitizing 
mutations such as L858R.5 Regarding T790M, it should be 
noted that one research group failed to demonstrate enhanced 
phosphorylation of these proteins in cells with the EGFR 
T790M + L858R mutations,4 whereas the same group later 
demonstrated increased phosphorylation in such cells.26 These 
observations suggest that the experimental conditions can 
influence the results of phosphorylation assay in the EGFR 
signaling pathway; therefore, further investigations in differ-
ent experimental settings would be required to confirm our 
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built using the homology modeling 
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results. Alternatively, mechanisms other than EGFR/STAT5/
ERK phosphorylation may contribute to tumor progression 
in V843I/L858R double-positive cells. A previous study sug-
gested, for example, that mutated EGFR activates the gp130/
JAK/STAT3 pathway by means of IL-6 upregulation, leading 
to tumor development.27 To assess the tumorigenic properties 
of EGFR T790M more directly, several groups have devel-
oped mouse models harboring the T790M mutation in lung 
epithelial cells. These mice frequently developed lung tumors 
without administration of tumor-inducing agents, indicating 
that this mutation is associated with spontaneous tumor for-
mation.28,29 We are currently developing a mouse model with 
a germ-line EGFR (V843I) mutation to directly investigate 
whether this mutation can contribute to lung tumorigenesis 
through the accumulation of additional EGFR mutations.
It is also interesting to note that addition of EGF 
enhances the kinase activity of cells with the EGFR (V843I) 
mutation. This observation is encouraging in applying ther-
apy using anti-EGFR monoclonal antibodies (cetuximab, for 
example) for lung cancer with the V843I mutation. In lung 
cancer cells harboring the T790M mutation, dual targeting 
of EGFR by cetuximab and erlotinib is reported to overcome 
resistance to TKIs.30 Further investigation will be needed to 
explore such possible therapies.
As previously reported, cells expressing a double-mutant 
(V843I + L858R) EGFR exhibited resistance to AG1478 both 
in vivo and in vitro.8 In the present study, drug sensitivity 
assays using erlotinib or gefitinib confirmed that this double 
mutation was associated with resistance to multiple EGFR-
TKIs. In addition, the cell line with the double mutation 
was resistant to afatinib and dacomitinib, second-generation 
EGFR TKIs that are effective for lung cancers with the T790M 
mutation.22 These results are notable considering the previous 
report that, whereas approximately 14% of lung cancers har-
bored secondary mutations in combination with sensitizing 
mutations in EGFR, most such secondary mutations did not 
affect the clinical response to TKIs.31 To test how the struc-
tural features of the mutated EGFR might cause resistance to 
TKIs, we performed protein modeling of EGFR with muta-
tions (L858R, T790M, L858R + V843I, and L858R + T790M 
substitutions). Our analysis predicted that conformational 
changes in the altered EGFR protein may impede erlotinib’s 
access to the EGFR TKI binding site. These results support 
the hypothesis that the mutated EGFR (L858R + V843I) con-
fers resistance to EGFR-TKIs through structural changes in 
EGFR. Cells harboring this double-mutated gene are resistant 
to second-generation EGFR-TKIs, meaning that development 
of novel therapeutic agents will be required to overcome the 
resistance because of the EGFR V843I mutation.
To explore the possibility that specific inhibition of 
EGFR V843I may restore sensitivity to AG1478 in cells har-
boring the mutant protein, we performed RNA inhibitory 
assays using allele-specific siRNAs. Treatment of KCI-PLA1 
cells (which express EGFR with the double-mutant V843I + 
L858R) with V843I-specific siRNAs rendered these cells sus-
ceptible to AG1478, whereas treatment with a control siRNA 
did not. A large part of the cells killed by siRNA underwent 
apoptosis, suggesting that the effect of V843I-specific siRNA 
occurs through suppression of EGFR rather than nonspecific 
toxicity.23 In contrast, treatment of NCI-H1975 cells (with 
EGFR protein with T790M + L858R) or of A549 cells (with 
wt EGFR) with V843I-specific siRNAs did not alter TKI sus-
ceptibility. These results together may demonstrate the allele-
specific role of the V843I substitution in providing resistance 
to TKIs in lung cancer. These results also are notable in the 
clinical context: treatment using an allele-specific inhibitor of 
EGFR V843I may be useful in overcoming TKI resistance in 
lung cancer patients with the EGFR (V843I) mutation. Thus, 
these findings may lead to development of promising thera-
peutic options for uncontrollable lung cancer in patients with 
specific mutations.
In conclusion, this study elucidated a part of the mecha-
nism underlying tumorigenesis and resistance to EGFR-TKIs 
in cells harboring the EGFR V843I mutation. These features 
are comparable with those seen in patients harboring an EGFR 
T790M mutation, suggesting that cases with germ-line V843I 
or T790M mutations could be categorized as a class of famil-
ial lung cancer syndrome with resistance to EGFR-TKIs.
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